NXTC NextCure, Inc.
USHealthcareAs of 2026-07-10 16:00
Why NXTC matters now
NextCure, Inc. (NXTC) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.97 with -1.50% on the session and $5.3M in market capitalization; recent performance reads 1-month -77.88% and YTD -85.76%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-9.8M, and EPS of $-1.87. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -923.4%.
The latest indexable market news headline is "3 Cancer Stocks to Watch as Oncology Innovation Accelerates" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Buy with a median target of $15.00; recent insider activity includes Cobourn Steven P. filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.40
P/S
0.00
EV/EBITDA
0.09
DCF Value
$6.70
FCF Yield
-923.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-187.0%
ROA
-143.9%
ROIC
-174.6%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-9.8M | $-1.87 |
| Q4 2025 | $0.00 | $-9.4M | $-2.69 |
| FY 2025 | $0.00 | $-55.8M | $-19.65 |
| Q3 2025 | $0.00 | $-8.6M | $-3.22 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$15.00
Target (Median)
$15.00
Target Range
$15.00 - $15.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.31
NextCure, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative immunotherapies. Its core mission is to combat cancer and various other immune-related conditions by reactivating normal immune system function. The company's leading investigational compound, NC318, is currently in Phase II clinical trials, focusing on the treatment of advanced or metastatic solid tumors. Additionally, NextCure is progressing NC410 through Phase I studies; this novel immunomedicine is engineered to counteract immune suppression mediated by Leukocyte-Associated Immunoglobulin-like Receptor 1 (LAIR-1). Another asset, NC762, is an immunotherapeutic designed to target the human B7 homolog 4 protein (B7-H4). Furthermore, NC525, a distinct LAIR-1 antibody, is undergoing preclinical assessment for its potential efficacy against acute myeloid leukemia, specifically targeting blast cells and leukemic stem cells. Beyond these specific pipeline candidates, NextCure's broader research and development efforts encompass the preclinical evaluation of other promising immunomodulatory antibodies and molecules. The company operates under a licensing agreement with Yale University. NextCure, Inc. was established in 2015 and maintains its corporate headquarters in Beltsville, Maryland.